FWG Holdings LLC Raises Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FWG Holdings LLC boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,591 shares of the medical equipment provider’s stock after buying an additional 101 shares during the quarter. FWG Holdings LLC’s holdings in Zimmer Biomet were worth $372,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the 3rd quarter worth about $28,000. Crewe Advisors LLC acquired a new stake in Zimmer Biomet during the first quarter worth about $31,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the third quarter valued at approximately $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet in the second quarter valued at approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Zimmer Biomet in the second quarter valued at approximately $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.4 %

ZBH opened at $113.02 on Tuesday. The firm has a market capitalization of $22.50 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 2.07 and a beta of 1.02. The company’s 50 day simple moving average is $106.45 and its two-hundred day simple moving average is $109.94. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.65 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s payout ratio is 18.25%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Evercore ISI cut their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. BTIG Research lowered their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Raymond James cut their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.